HSPG2 and thanatophoric dysplasia: At present, the reports of TD caused by immunosuppressant PD-1 monoclonal antibody treatment mostly come from clinical trials, rather than real-world studies, especially less studies of PD-1 monoclonal antibody treatment of PLC.